Skip to main content

Education/ACR/EULAR

      RT @uptoTate: A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures
      4 years 6 months ago
      A study worth remembering. Pts with FM-PsA had statistically higher PsA dz activity in subjective measures ONLY, not in objective measures. Make sure you take time to fully treat your patients and give them tools for FM as well as PsA. #EULAR2020 @RheumNow #AB0731 https://t.co/e3JkEmq3EZ
      RT @uptoTate: SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No ne
      4 years 6 months ago
      SELECT-PSA-2 results: UPA15 & UPA30 showed improvement across PsA domains vs PBO through Wk 24. No new safety signals were identified. Check out abstract #OP0223 for the MDA/ACR50/ACR70 responses. #EULAR2020 @RheumNow https://t.co/UAx2tkKSZI
      RT @uptoTate: #EULAR2020 press conference report: Global Rheum Alliance for COVID19 and Eular registries provide reassur
      4 years 6 months ago
      #EULAR2020 press conference report: Global Rheum Alliance for COVID19 and Eular registries provide reassurance to rheums and pts regarding immunosuppression and COVID19. The compiled data from over 600 pts in 40 countries. @RheumNow https://t.co/qMwGJTL041
      RT @uptoTate: Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumN
      4 years 6 months ago
      Do you use different medications for different PsA domains? Teach me how you practice! #EULAR2020 @RheumNow
      RT @uptoTate: Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383
      4 years 6 months ago
      Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6
      RT @uptoTate: Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in thi
      4 years 6 months ago
      Interestingly, first line use was the only predictor of improved retention of SEC in axSpA patients in this French study. Poster #THU0386 #EULAR2020 @RheumNow https://t.co/keI9xGWKCL https://t.co/avLtJzaEOc
      RT @uptoTate: Obesity is a strong predictor of worse clinical course and treatment response in AS. Poster #THU0389 #EULA
      4 years 6 months ago
      Obesity is a strong predictor of worse clinical course and treatment response in AS. Poster #THU0389 #EULAR2020 @RheumNow https://t.co/Zb2RrqSIaK https://t.co/2z1HMQ3b5G
      RT @uptoTate: This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA pati
      4 years 6 months ago
      This Turkish study found that obesity did NOT play a roll in tx efficacy/retention using SEC in axSpA patients. #EULAR2020 Poster #THU0390 @RheumNow https://t.co/z3imYNuxYq https://t.co/sGz9cohH6T
      RT @uptoTate: Do you routinely discuss obesity with your rheum patients? #EULAR2020 @RheumNow
      4 years 6 months ago
      Do you routinely discuss obesity with your rheum patients? #EULAR2020 @RheumNow
      RT @uptoTate: nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated
      4 years 6 months ago
      nr-axSpA pts with active inflammation improved with IXE. Drug efficacy did not change in pts with elevated CRP or sacroiliitis or both. #EULAR2020 @RheumNow poster #THU0395 https://t.co/ap6Wy2eNBL https://t.co/zLoNHuSVV5
      ×